Compounds > 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
Page last updated: 2024-10-21

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Alzheimer Disease

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with Alzheimer Disease in 2 studies

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist

Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Porter, RH2
Roberts, PJ2
Briggs, RS2
Cowburn, RF1
Alasuzoff, I1

Other Studies

2 other studies available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Alzheimer Disease

ArticleYear
NMDA receptor status in elderly normal individuals and those with Alzheimer's disease.
    Annals of the New York Academy of Sciences, 1993, Sep-24, Volume: 695

    Topics: Aged; Alzheimer Disease; Brain; Humans; Piperazines; Radioligand Assay; Receptors, N-Methyl-D-Aspart

1993
Heterogeneity of NMDA receptors labelled with [3H]3-((+-)-2-carboxypiperazin-4-yl) propyl-1-phosphonic acid ([3H]CPP): receptor status in Alzheimer's disease brains.
    European journal of pharmacology, 1992, Mar-12, Volume: 225, Issue:3

    Topics: 2-Amino-5-phosphonovalerate; Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Animals; Bindi

1992